Required Agreement Terms for All Practice Settings Sample Clauses

Required Agreement Terms for All Practice Settings. In addition to specific practice setting collaborative practice agreement requirements, pursuant to 247 CMR 16.03, and in accordance with M.G.L. c. 112, § 24B¾ and 243 CMR 2.12, all collaborative practice agreements must also include: (a) specific disease state(s) being co-managed, with each disease state identified as either primary or co-morbid; (b) specific pharmacist prescribing authority pursuant to the CDTM agreement; (c) detailed practice protocols; (d) description of risk management activities; (e) documentation of any initiation, modification or discontinuation of a patient's medication in the patient's permanent medical record; (f) description of outcome measurements; (g) detailed informed consent procedures appropriate to the practice setting; (h) detailed procedures and periods by which time any test results, copies of initial prescriptions, modifications or discontinuances, copies of the patient consent and the CDTM agreement, and other patient information will be forwarded by the authorized pharmacist to the supervising physician, and a specific procedure for the authorized pharmacist to identify and transmit any urgent communications; description of the nature and form of the super- vision of the authorized pharmacist by the supervising physician, and a description of the procedure to follow when either the authorized pharmacist or supervising physician is unavailable or absent;

Required Agreement Terms for All Practice Settings. In addition to specific practice setting collaborative practice agreement requirements, pursuant to 247 CMR 16.03, and in accordance with M.G.L. c. 112, § 24B¾ and 243 CMR 2.12, all collaborative practice agreements must also include: specific disease state(s) being co-managed, with each disease state identified as either primary or co-morbid; specific pharmacist prescribing authority pursuant to the CDTM agreement; detailed practice protocols; description of risk management activities; documentation of any initiation, modification or discontinuation of a patient's medication in the patient's permanent medical record; description of outcome measurements; detailed informed consent procedures appropriate to the practice setting; detailed procedures and periods by which time any test results, copies of initial prescriptions, modifications or discontinuances, copies of the patient consent and the CDTM agreement, and other patient information will be forwarded by the authorized pharmacist to the supervising physician, and a specific procedure for the authorized pharmacist to identify and transmit any urgent communications; description of the nature and form of the super­ vision of the authorized pharmacist by the supervising physician, and a description of the procedure to follow when either the authorized pharmacist or supervising physician is unavailable or absent; (1) for participating in collaborative drug therapy management; and